Navigation Links
Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
Date:6/1/2009

On Saturday, May 30, Dr. Kim Nguyen Chi, principle investigator and a medical oncologist at BC Cancer Agency - Vancouver Centre, presented the final results of a randomized Phase 2 trial of OGX-011 in patients with advanced metastatic prostate cancer. In this trial, OncoGenex reported that a median overall survival was observed in patients treated with OGX-011 plus docetaxel of 23.8 months compared to 16.9 months for patients treated with docetaxel alone, the current standard of care for patients with advanced metastatic prostate cancer. In addition, OncoGenex reported that the unadjusted hazard ratio, a measure used to determine the difference in survival between treatment groups was 0.61, representing a 39% reduction in the rate of death for patients treated with OGX-011. OGX-011 continues to be well tolerated in combination with docetaxel. Based on clinical results to date, OncoGenex has said that it intends to conduct Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to securing a development partner or the receipt of additional funding.

Dr. Sebastien Hotte, principle investigator and medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario, presented new data on Saturday May 30 from a Phase 1 study on OGX-427 in patients with a variety of cancers. In this study, Dr. Hotte reported declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer. For further details on both the OGX-011 and OGX-427 study results, please see OncoGenex' releases that were issued on Saturday May 30, 2009.

Also on Saturday May 30, Dr. Denis Talbot, clinical investigator and medical oncologist in the Medical Oncology Unit at The Churchill Hospital, Oxford Radcliffe Hospitals NHS Trust, presented new data from a Phase 1 study of LY2181308 in patients with can
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
2. New survey highlights growing concern about risk of infection in cancer patients
3. New Book Highlights Human Cost of FDAs Failure to Investigate Medical Devices
4. New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
5. FDAs Hydroxycut Recall Highlights the Need for Stem Cell Innovations ACTIVTox Human Liver Testing
6. Amgen Highlights Data to Be Presented at ASCO
7. Hospira Highlights Five Years of Progress and Future Opportunities at Its 2009 Annual Meeting of Shareholders
8. Dey, L.P. Highlights Perforomist(R) Inhalation Solution Data to Be Presented at the International Conference of the American Thoracic Society
9. Quality of life survey highlights need for holistic approach in elderly residential care
10. Saberi Release Highlights Case of Imprisoned Iranian AIDS Doctors
11. The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... "Many men refuse to touch the toilet in ... in urine and spit," said an inventor from Decorah, ... came up with this hygienic device." , He developed ... the toilet seat before urinating. The unit ends the ... with dirt and germs. The accessory prevents urine from ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market ... to 2018” defines and segments the global polycarbonate ... global revenue and consumption. It also identifies driving ... market with analysis of trends, opportunities, burning issues, ... and revenues are forecasted on the basis of ...
(Date:8/23/2014)... York (PRWEB) August 23, 2014 ... the 2012 GranuFlo and NaturaLyte dialysis concentrate recall ... underway in U.S. District Court, District of Massachusetts, ... docket report issued by the U.S. Judicial Panel ... least 2,028 claims are pending in the proceeding. ...
(Date:8/23/2014)... 23, 2014 Peripheral intervention surgeries are ... plaques, etc, thereby addressing the root cause of peripheral ... blood to the other part of the arteries where ... These procedures require the use of a catheter, (which ... polymers), these catheters are inserted through a thin cut ...
(Date:8/23/2014)... According to the new research report, "Electronic ... - Regional Trends & Forecast to 2019," defines ... analysis and forecast of value individually. Along with ... by applications and geography are also discussed in ... and 26 figures spread through 234 pages and ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3
... lutenizing hormone-releasing hormone agonist, reduces the long-term risk of ... breast cancer who did not take tamoxifen, according to ... of the Journal of the National Cancer Institute. ... hormone agonists, including goserelin, reduce the risk of disease ...
... to a cardiologist to go through a standard battery of ... coronary artery disease which is the most common cause of ... and these women are sent home with little more than ... similar symptoms and are more likely to develop future cardiac ...
... 24, 2009 Diagnosing acute stroke is a high-pressure ... all the difference. Early treatment can stop brain damage, ... increase the risk of bleeding in the brain. , ... stroke treatmenta clot-busting enzyme known as tissue plasminogen activator ...
... 23, 2009) Postpartum depression is a seriousand often ... mothers. Some of the causes might include personal history ... financial or emotional support. Left untreated, it can have ... on her child,s development. , In the ...
... Hanover Insurance Group, Inc. (NYSE: THG ... to the company,s board of directors at its ... principal of Taggart Associates in Cambridge, Mass., which ... work on corporate and non-profit boards.(Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ...
... that can pose a big public health threat, researchers ... their release from Texas prisons, only 5 percent of ... treat their condition within the necessary 10 days, a ... therapy] at this time are at increased risk of ...
Cached Medicine News:Health News:Goserelin improves long-term survival in premenopausal women with early breast cancer 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Stroke treated significantly faster and just as safely by medical residents 2Health News:Stroke treated significantly faster and just as safely by medical residents 3Health News:Diabetes a risk factor for postpartum depression 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 3Health News:Most HIV-Infected Prisoners Go Untreated After Release 2
(Date:8/22/2014)... , Aug. 22, 2014  Medical Science Liaisons serve ... leaders in the healthcare sector. As the impact of ... is changing how Medical Science Liaisons (MSLs) interact with ... are using the tablet to not only share important ... better coordinate thought leader interactions across geographies and therapeutic ...
(Date:8/22/2014)... , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition ... 2014-2018"  report to their offering.  ... is an essential instrument for any modern ... precise weighing of materials. It can be ...
(Date:8/22/2014)... , August 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... with a sterile environment in a healthcare ... is equipped with technically advanced equipment, which ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... Boston Scientific Corporation (NYSE: BSX ) announces ... be presented at Digestive Disease Week ® (DDW), ... involve the SpyGlass ® Direct Visualization System, WallFlex® ... Needle and Resolution® Clip. "The volume and ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... an Abbreviated New Drug Application (ANDA) with the ... to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and ... 75 mg. Watson,s ANDA product is a generic ...
Cached Medicine Technology:Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 2Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 3Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 4Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 5Watson Confirms Lo Loestrin® Fe Patent Challenge 2Watson Confirms Lo Loestrin® Fe Patent Challenge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: